Physician profile
Vicky C Pai
NPI 1740485895
$9,608.45
in general payments reported to CMS, 2019-2025
30 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $825 · 2021: $1,185 · 2022: $1,568 · 2023: $1,168 · 2024: $1,430 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,814 · Long Term Medical Supply Or Device Loan: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,814.42 |
| Long Term Medical Supply Or Device Loan | $160.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,759.65 | 2019-2025 | Clareon, Ngenuity, Rocklatan |
| Sun Pharmaceutical Industries INC. | $985.76 | 2019-2025 | Cequa |
| Abbvie INC. | $841.29 | 2022-2025 | |
| Allergan, INC. | $680.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $654.05 | 2019-2023 | |
| Sight Sciences, INC. | $575.53 | 2020-2025 | Omni Surgical System, Tearcare System |
| Tarsus Pharmaceuticals, INC. | $520.74 | 2024-2025 | Xdemvy |
| Nova Eye, INC. | $403.57 | 2025 | |
| Oyster Point Pharma, INC. | $376.37 | 2022-2025 | Tyrvaya |
| Arcutis Biotherapeutics, INC. | $335.95 | 2023-2024 | Zoryve |
| Biotissue Holdings INC. | $284.46 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $244.75 | 2019-2021 | |
| Ocular Therapeutix, INC. | $235.85 | 2022-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $212.81 | 2019-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Amgen INC. | $207.67 | 2024-2025 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $207.24 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $188.38 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Shire North American Group INC | $171.54 | 2019 | |
| Horizon Therapeutics Plc | $155.35 | 2022-2023 | Tepezza |
| Galderma Laboratories, L.P. | $128.50 | 2022 | |
| Eyevance Pharmaceuticals LLC | $80.05 | 2019-2022 | |
| Thea Pharma INC. | $69.51 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $68.02 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $48.84 | 2019-2020 | |
| Dompe US, INC. | $48.67 | 2023-2024 | Oxervate |
| Ivantis, INC | $47.07 | 2021 | |
| Eyepoint US, INC. | $39.30 | 2019 | |
| Omeros Corporation | $19.71 | 2019 | |
| Akorn, INC. | $16.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.